NEW YORK, NY / ACCESSWIRE / July 18, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the lead plaintiff deadlines listed below to petition the court, and those interested in their eligibility are encouraged to contact the firm. There will be no cost or obligation to you.
Livent Corporation (LTHM)
Lawsuit on behalf of: investors who purchased on behalf of persons and entities that purchased or otherwise acquired Livent securities pursuant and/or traceable to initial public offering on or around October 11, 2018.
Lead Plaintiff Deadline : July 22, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/livent-corporation-loss-form?prid=2479&wire=1
According to the filed complaint, (1) a supply contract with Nemaska Lithium Inc. had been terminated; (2) as a result, the Company would be forced to fulfill its customer contracts using alternative vendors at reduced revenues and lower margins; (3) the Company had a long-standing contract to supply lithium hydroxide to a customer at a much lower price than any of the Company's existing contracts; (4) the Company's margins were squeezed due to the customer's increased orders; and (5) as a result of the foregoing, Defendants positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Heron Therapeutics, Inc. (HRTX)
Lawsuit on behalf of: investors who purchased October 31, 2018 - April 30, 2019
Lead Plaintiff Deadline : August 5, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/heron-therapeutics-inc-loss-form?prid=2479&wire=1
According to the filed complaint, during the class period, Heron Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.
Ra Medical Systems, Inc. (RMED)
Lawsuit on behalf of: investors who purchased stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ra-medical-systems-inc-loss-form?prid=2479&wire=1
According to the filed complaint, (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: